查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球去中心化临床试验成长机会
市场调查报告书
商品编码
1358186

全球去中心化临床试验成长机会

Global Decentralized Clinical Trials Growth Opportunities
出版日期: | 出版商: Frost & Sullivan | 英文 84 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

日益激烈的竞争推动了全球范围内的 DCT 计划，为基于合作伙伴关係的成长模式铺平了道路

自COVID-19大流行以来，全球去中心化临床试验（DCT）市场持续快速成长。 2020年加速引入DCT的背景是，参与临床试验的临床实验临床实验、临床实验临床实验合作者和患者的流动受到限制，全球临床实验活动大幅停顿。为了确保病患安全和研发活动的连续性，大多数临床试验赞助者和委外研发机构(CRO) 正在使用直接资料收集来支援远端医疗、远端来源资料检验和感测器/行动技术。我们采用了数位工具，例如支援临床实验业务的解决方案。

世界各地的法规机构正在与 DTRA（去中心化试验和研究联盟）等现有联盟一起，推出大规模实施 DCT 模式的倡议和指南，旨在提高 DCT 的认识。我们支持引入测试。

北美凭藉强大的 DCT 供应商、CRO 和製药赞助商继续引领 DCT 市场。然而，亚太地区正在成为一个重要的地区，由于其患者多样性、未经治疗的人群和显着的成本优势，全球几家主要的 CRO 都建立了牢固的立足点。此外，该地区越来越依赖远端医疗和电子药局解决方案，DCT 将在未来三到五年内变得更加普及。在世界其他地方，中东正准备扩大远端试验的使用，其中沙乌地阿拉伯和杜拜处于领先地位。包括 Oracle 和 AWS 在内的多家技术供应商均位于该地区，支援电子临床解决方案的部署并推动成长。然而，与其他地区相比，该市场目前的成长相对缓慢。

始终需要透过适合用途的云端基础的平台解决方案来支援分散的临床试验。因此，CRO正在透过与技术供应商合作来建立分散式测试能力。此外，针对患者的线上培训模组以及使用设备、聊天机器人和感测器进行家庭测试监控的安全技术正在支援大流行后采用分散式测试。

为因残疾或地点而受到限制的患者提供居家医疗服务可以促进临床试验的持续。与受过便携式设备使用培训的护理人员支援的居家医疗服务提供者合作，有助于 DCT 的顺利实施。此外，CRO 正在探索多种管道，透过扩大 DCT 生态系统来创新试验註册和病人参与策略，包括倡导团体、社交媒体、使用线上医生转诊系统以及部署人工智慧平台。我正在关注这一点。

目录

战略问题

  • 为什么成长如此困难？
  • The Strategic Imperative 8（TM）
  • 分散临床试验（DCT）产业三大策略重点的影响
  • 成长机会推动Growth Pipeline Engine（TM）

成长机会分析：去中心化临床试验市场

  • 分析范围
  • 分散式临床试验市场的细分
  • 成长指标
  • 传统和分散临床试验的比较
  • DCT 的价值提案实现以病人为中心
  • 去中心化的临床试验药物生态系统
  • 去中心化的临床试验患者生态系统

市场概述

  • 市场趋势分析
  • 不断变化的 DCT形势
  • 全球 DCT 倡议和指南
  • DCT计画对全球DCT市场的影响
  • DCT配合措施对各个相关人员的影响
  • 成长促进因素
  • 成长阻碍因素
  • DCT：不断发展的供应商生态系统

商业模式趋势

  • 商业模式趋势：全球 DCT 市场
  • 推动 DCT 商业模式的合作趋势
  • DCT市场策略伙伴关係

透过併购和平台/产品推出扩大产能

  • 主要併购
  • 新平台推出

成长机会分析：收益和预测分析，世界

  • 预测假设
  • 收益预测：全球
  • 收益预测分析
  • 按临床开发阶段分類的收益预测
  • 按开发阶段分類的收入比例
  • 按临床开发阶段分類的收益预测
  • 按治疗领域分類的收益占有率分析
  • 按治疗领域分類的收益占有率分析

成长机会分析：区域收益预测分析

  • 地区收益预测
  • DCT市场区域收益预测分析
  • 收益预测分析：北美
  • 收益预测分析：北美欧洲
  • 收益预测分析：欧洲亚太地区 (APAC)
  • 收益预测分析：亚太地区 (APAC) 世界其他地区 (RoW)

竞争环境

  • 竞争环境
  • 竞争基准化分析：Pure Play DCT 供应商
  • 竞争基准化分析：CRO（推动者/DCT 供应商）
  • 竞争基准化分析DCT 推动者
  • 竞争评估

成长机会宇宙

  • 成长机会 1：使用数位生物标记进行终点评估
  • 成长机会2：专注于使用数位健康技术（DHT）进行肿瘤学检测
  • 成长机会3：采用基于合作关係的方法来扩展DCT能力

下一步

  • 下一步
  • 为什么是霜冻，为什么是现在？
  • 附件清单
  • 免责声明
简介目录
Product Code: PF10-52

Strong Competitive Intensity is Advancing DCT Initiatives Across the World Paving Way for a Partnership-based Growth Model

The global decentralized clinical trial (DCT) market has been witnessing a continued surge after the COVID-19 pandemic. The accelerated DCT adoption in 2020 was driven by restricted mobility of site investigators, clinical research associates, and patients to participate in trials, which resulted in a significant halt in trial activities worldwide. To ensure patient safety and continuity in the R&D activities, most sponsors and contract research organizations (CROs) adopted digital tools to support trial operations, including telemedicine, remote source data verification, and sensor/mobile technology-enabled direct data-capture solutions.

Regulatory agencies around the world are coming up with initiatives and guidelines for large-scale adoption of DCT modalities, alongside existing alliances, such as Decentralized Trials & Research Alliance (DTRA), that work toward increasing DCT awareness, propelling remote trial uptake.

North America continues to lead the DCT market owing to a strong presence of DCT vendors, CROs, and pharma sponsors in the region, followed closely by Europe, which has abundant infrastructure for large-scale DCT uptake. Nevertheless, Asia-Pacific is emerging as a crucial region with several leading global CROs establishing strong bases due to patient diversity, treatment-naive population, and significant cost advantage. In addition, there is a growing reliance on telemedicine and ePharmacy solutions in the region, which will propel DCT uptake in 3 to 5 years. In the Rest of World region, the Middle East is gearing up for greater remote trial adoption, with Kingdom of Saudi Arabia and Dubai at the forefront. Several tech vendors, such as Oracle and AWS, have set up bases in the region to allow the uptake of eClinical solutions, promoting growth. However, at present, the market will have comparatively slower growth than other regions.

There will be a constant need to support decentralized trials through cloud-based platform solutions that are fit to purpose. Therefore, CROs are building decentralized trial capabilities by partnering with technology vendors. In addition, online training modules for patients and secure technology for at-home trial monitoring through devices, chatbots, and sensors have been driving the adoption of decentralized trials after the pandemic.

Home health services for patients with physical disabilities and restricted access due to location can promote retention in clinical trials. Partnering with home health service providers supported by nurses trained in portable equipment usage will facilitate smooth DCT implementation. In addition, CROs are focused on innovating trial enrollment and patient engagement strategies by exploring multiple channels, such as the use of advocacy groups, social media, and online physician referral systems, as well as implementing AI-enabled platforms, expanding the DCT ecosystem.

Table of Contents

Strategic Imperatives

  • Why Is It Increasingly Difficult to Grow?
  • The Strategic Imperative 8™
  • The Impact of the Top 3 Strategic Imperatives on the Decentralized Clinical Trial (DCT) Industry
  • Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Analysis: Decentralized Clinical Trial Market

  • Scope of Analysis
  • Decentralized Clinical Trials Market Segmentation
  • Growth Metrics
  • Comparison of Traditional and Decentralized Clinical Trials
  • DCT Value Proposition: Achieving Patient Centricity
  • Decentralized Clinical Trials: Pharma Ecosystem
  • Decentralized Clinical Trials: Patient Ecosystem

Market Snapshot

  • Market Trend Analysis
  • Evolving DCT Landscape
  • Global DCT Initiatives and Guidelines
  • Implications of DCT Initiatives on the Global DCT Market
  • Implications of DCT Initiatives on Individual Stakeholders
  • Growth Drivers
  • Growth Restraints
  • DCT: Evolving Vendor Ecosystem

Business Model Trends

  • Business Model Trend: Global DCT Market
  • Partnership Trends Driving DCT Business Models
  • Strategic Partnerships in DCT Market

Expanding Capabilities with M&As and Platform/Product Launches

  • Key Mergers and Acquisitions
  • New Platform Launches

Growth Opportunity Analysis: Revenue Forecast Analysis, Global

  • Forecast Assumptions
  • Revenue Forecast: Global
  • Revenue Forecast Analysis
  • Revenue Forecast by Phases of Clinical Development
  • Revenue Percentage by Phase of Development
  • Revenue Forecast by Clinical Development Phases
  • Revenue Share Analysis by Therapy Areas
  • Revenue Share Analysis by Therapy Areas

Growth Opportunity Analysis: Revenue Forecast Analysis, By Regions

  • Revenue Forecast by Regions
  • Revenue Forecast Analysis by Region: DCT Market
  • Revenue Forecast Analysis: North America
  • Revenue Forecast Analysis: Europe
  • Revenue Forecast Analysis: Asia-Pacific (APAC)
  • Revenue Forecast Analysis: Rest of World (RoW)

Competitive Environment

  • Competitive Environment
  • Competitor Benchmarking: Pure-play DCT Vendors
  • Competitor Benchmarking: CROs (Enablers/DCT Vendors)
  • Competitor Benchmarking: DCT Enablers
  • Competitor Assessment

Growth Opportunity Universe

  • Growth Opportunity 1: Endpoint Assessment with Digital Biomarkers
  • Growth Opportunity 2: Digital Health Technology (DHT)-enabled Focus on Oncology Trials
  • Growth Opportunity 3: Adopting Partnership-based Approaches for Scaling DCT Capabilities

Next Steps

  • Your Next Steps
  • Why Frost, Why Now?
  • List of Exhibits
  • Legal Disclaimer